Evidence mapPaperPMID 32045421Full record

SynthesisPloS one2020

The effects of omega-3 fatty acids on diabetic nephropathy: A meta-analysis of randomized controlled trials.

Api Chewcharat, Pol Chewcharat, Anawin Rutirapong, Stefania Papatheodorou

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 4 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. The Impact of Omega Fatty Acids on DKD: A Multimodal Study Integrating Mendelian Randomization, Proteomic Mediation Analysis, and Meta-Analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Nutritional Values of Teff (Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Review
  16. Review
  17. Review
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Api ChewcharatDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.ORCID 0000-0002-1707-9988
Pol ChewcharatDepartment of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Anawin RutirapongDepartment of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Stefania PapatheodorouDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.
Chulalongkorn University · THHarvard University · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effects of omega-3 long-chain polyunsaturated fatty acids on proteinuria, estimated glomerular filtration rate (eGFR) and metabolic biomarkers among patients with diabetes. STUDY

designMeta-analysis of randomized controlled clinical trials (RCTs). SETTING & SUBJECTS: Patients with diabetes. SELECTION CRITERIA FOR STUDIES: We conducted electronic searches in PubMed, Embase and Cochrane Central Register of Controlled Trials from January 1960 to April 2019 to identify RCTs, which examined the effects of omega-3 fatty acids on proteinuria, eGFR and metabolic biomarkers among diabetic patients.

resultsTen RCTs with 344 participants were included in our meta-analysis. Omega-3 fatty acids reduced the amount of proteinuria among type 2 diabetes mellitus (type 2 DM) and type 1 diabetes mellitus (type 1 DM). This association was only significant among type 2 DM (SMD = -0.29 (95% CI: -0.54, -0.03; p = 0.03). Only studies with duration of intervention of 24 weeks or longer demonstrated a significant lower proteinuria among omega-3 fatty acids compared to control group (SMD = -0.30 (95% CI: -0.58, -0.02; p = 0.04). There was a higher eGFR for both type 1 and type 2 DM groups among omega-3 fatty acids compared to control group, however, the effect was not statistically significant. Regarding serum total cholesterol, LDL-cholesterol and HbA1C, there was no significant difference comparing omega-3 fatty acids to control group. There was a non-significant systolic blood pressure reduction in the omega-3 fatty acids supplementation group compared to control.

conclusionOmega-3 fatty acids could help ameliorate proteinuria among type 2 DM who received omega-3 supplementation for at least 24 weeks without adverse effects on HbA1C, total serum cholesterol and LDL-cholesterol.

Indexed as

BiomarkersCholesterolCholesterol, LDLDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Fatty Acids, Omega-3Glomerular Filtration RateGlycated HemoglobinHumansProteinuriaRandomized Controlled Trials as TopicBiomarkersCholesterolCholesterol, LDLFatty Acids, Omega-3Glycated Hemoglobinhemoglobin A1c protein, human

Identifiers

PMID32045421
PMCPMC7012392
OpenAlexW3005711463

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.